Enoxaparin 40 Mg/0.4 mL Injectable Solution

DRUG2 trials

Sponsors

IRCCS Azienda Ospedaliero-Universitaria di Bologna, General Committee of Teaching Hospitals and Institutes, Egypt

Conditions

Anastomotic LeakageBlood LossBlood TransfusionCOVID-19Intensive CareLymph Node DiseaseSurvival

Phase 2

Enoxaparin in COVID-19 Moderate to Severe Hospitalized Patients

CompletedNCT04427098

IRCCS Azienda Ospedaliero-Universitaria di BolognaCOVID-19

Start: 2020-05-22End: 2021-09-29Updated: 2024-12-03

Unknown Phase

D2 Versus D3 Dissection in Laparoscopic Right Hemicolectomy

Not yet recruitingNCT06049758

General Committee of Teaching Hospitals and Institutes, EgyptAnastomotic Leakage, Blood Loss, Blood Transfusion +3

Start: 2024-01-02End: 2030-01-02Target: 80Updated: 2023-09-22

Related Papers

Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19.

2023-10-242 citations